Cloud-Clone expands feline primary cell supply for research labs

Cloud-Clone says it is exporting a broad portfolio of quality-validated feline primary cells worldwide to fill a gap in comparative medicine, veterinary disease modeling and regenerative research. The company says the collection includes multiple tissue systems, matched culture media and detection reagents, backed by ISO-certified workflows and contamination screening.

Why it matters: - Feline primary cells are a scarce research tool, even as demand rises for more physiologically relevant models in comparative medicine and translational studies. - The shortage affects work on feline disease, zoonotic conditions, tissue repair and regenerative medicine. - Cloud-Clone is positioning its portfolio as a supply source for labs that need standardized feline-origin cells with stable batch performance.

What happened: - Cloud-Clone announced a worldwide export program for feline primary cells from HUSTON, Texas, on November 3, 2026. - The company says the portfolio is designed to support research groups studying comparative medicine, veterinary disease modeling and regenerative medicine. - Cloud-Clone also says it provides matched cell-culture media and detection reagents to support downstream work. - More information is available in the company's announcement.

The details: - The feline primary-cell portfolio spans nervous, cardiovascular, musculoskeletal, digestive, urological and respiratory systems. - The lineup includes feline cerebral astrocytes, meningeal cells, cardiac microvascular endothelial cells, cardiomyocytes, articular chondrocytes, synoviocytes, gastric mucosal epithelial cells, renal tubular epithelial cells, bladder epithelial cells, tracheal epithelial cells and pulmonary fibroblasts. - Additional cell types cover endocrinology-metabolism, reproductive biology, immunology-inflammation, dermatology, ophthalmology and odontostomatology research. - Examples include pre-adipocytes, adipose-derived mesenchymal stem cells, endometrial epithelial cells, ovarian granulosa cells, bone-marrow mononuclear cells, peripheral-blood mononuclear cells, epidermal keratinocytes, corneal epithelial cells and gingival fibroblasts. - Cloud-Clone says the product range supports studies of disease mechanisms, drug screening, tissue damage repair and regenerative medicine. - The company says the cells are isolated, cultivated and identified through standardized workflows built specifically for feline primary cells.

Between the lines: - The release reflects a niche-market strategy: most major primary-cell suppliers focus on human cells and common rodent lines. - Cloud-Clone is trying to stand out by offering species-specific coverage, supporting reagents and worldwide distribution in a segment with few vendors. - The company says its quality-control framework is meant to reduce the variability that often makes primary-cell sourcing difficult for specialized research programs.

What's next: - Cloud-Clone says it will continue optimizing its feline primary-cell portfolio and supporting reagent ecosystem. - The company expects demand for non-human primary-cell models to keep rising as comparative-medicine and veterinary-translational research expands. - Researchers can review the full collection through more information.

The bottom line: - Cloud-Clone is betting that a rare mix of breadth, quality control and global supply can make feline primary cells easier for research labs to source and use.